Erica K Berggren1, Hilary A Roeder2, Kim A Boggess3, Kevin Moss4, Steven Offenbacher4, Emilia Campbell5, Chad A Grotegut5. 1. Department of Obstetrics and Gynecology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA erica.berggren@gmail.com. 2. Department of Obstetrics and Gynecology, University of California, San Diego, San Diego, CA, USA. 3. Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 5. Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA.
Abstract
OBJECTIVE: We evaluated whether first-trimester high-sensitivity C-reactive protein (hsCRP), a suggested marker of pregnancy-associated hyperglycemia, predicts third-trimester impaired glucose tolerance (IGT) in a secondary analysis of a prospective cohort of nondiabetic singletons enrolled at <26 weeks gestation. STUDY DESIGN: We measured the association between hsCRP collected at <14 weeks among women classified as IGT (gestational diabetes screening results, 135 to <200 mg/dL) and those among normoglycemic women. Multivariable modeling estimated the association between log hsCRP and IGT, adjusted for maternal body mass index (BMI). RESULTS: Among 300 women, 13% (39 of 300) had IGT. The hsCRP was positively associated with glucose (P = .005). Compared with normoglycemic women, women with IGT had higher log hsCRP (0.87 ± 0.66 vs 0.67 ± 0.60, P = .04), but the association was not significant in adjusted models (adjusted odds ratio 1.20, 95% confidence interval 0.65-2.21). The hsCRP did not predict third-trimester IGT in this analysis when BMI is considered. CONCLUSION: Early identification of women at risk of IGT remains a priority, but the contribution of maternal BMI appears greater than hsCRP.
OBJECTIVE: We evaluated whether first-trimester high-sensitivity C-reactive protein (hsCRP), a suggested marker of pregnancy-associated hyperglycemia, predicts third-trimester impaired glucose tolerance (IGT) in a secondary analysis of a prospective cohort of nondiabetic singletons enrolled at <26 weeks gestation. STUDY DESIGN: We measured the association between hsCRP collected at <14 weeks among women classified as IGT (gestational diabetes screening results, 135 to <200 mg/dL) and those among normoglycemic women. Multivariable modeling estimated the association between log hsCRP and IGT, adjusted for maternal body mass index (BMI). RESULTS: Among 300 women, 13% (39 of 300) had IGT. The hsCRP was positively associated with glucose (P = .005). Compared with normoglycemic women, women with IGT had higher log hsCRP (0.87 ± 0.66 vs 0.67 ± 0.60, P = .04), but the association was not significant in adjusted models (adjusted odds ratio 1.20, 95% confidence interval 0.65-2.21). The hsCRP did not predict third-trimester IGT in this analysis when BMI is considered. CONCLUSION: Early identification of women at risk of IGT remains a priority, but the contribution of maternal BMI appears greater than hsCRP.
Authors: Susan Lieff; Kim A Boggess; Amy P Murtha; Heather Jared; Phoebus N Madianos; Kevin Moss; James Beck; Steven Offenbacher Journal: J Periodontol Date: 2004-01 Impact factor: 6.993
Authors: Kim A Boggess; Susan Lieff; Amy P Murtha; Kevin Moss; Heather Jared; James Beck; Steven Offenbacher Journal: Am J Perinatol Date: 2005-08 Impact factor: 1.862
Authors: Ravi Retnakaran; Anthony J G Hanley; Nuryt Raif; Philip W Connelly; Mathew Sermer; Bernard Zinman Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958
Authors: John P Bantle; Judith Wylie-Rosett; Ann L Albright; Caroline M Apovian; Nathaniel G Clark; Marion J Franz; Byron J Hoogwerf; Alice H Lichtenstein; Elizabeth Mayer-Davis; Arshag D Mooradian; Madelyn L Wheeler Journal: Diabetes Care Date: 2008-01 Impact factor: 19.112